journal logo
  • search
  • open the menu

Intro Pullout Text Widget

Annals of the Rheumatic Diseases (ARD)

is a leading rheumatology journal from BMJ and EULAR, publishing original research, reviews and recommendations

Impact Factor: 19.103
Citescore: 28.5
All metrics >> 

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

ARD is an official journal of EULAR.

Free lay summaries are provided for selected research articles and all EULAR recommendations. You can keep up with the latest news via Twitter and Facebook.

Podcast iconListen to the ARD podcast and subscribe in all podcast platforms, including Apple Podcast, Google Podcasts, Stitcher and Spotify.

Editor-in-Chief: Professor Josef Smolen, Medical University of Vienna, Austria
Editorial team

ARD is a Plan S compliant Transformative Journal.

Latest Content
Annals of the Rheumatic Diseases

Key Articles from the last 75 years

Highlighted Articles

Authors

Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.
 
The Author Information section provides general guidelines and requirements for specific article types.
 
Information is also provided on editorial policies and open access.

EULAR Recommendations

The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.

 

All EULAR recommendations are free to access. 

 

Each recommendation also has an accompanying lay summary, which is also free to access.

Video Abstract

Concordance and discordance in SLE clinical trial outcome measures

To cite: Bruce IN, Furie RA, Morand EF, et alConcordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trialsAnnals of the Rheumatic Diseases Published Online First: 17 May 2022. doi: 10.1136/annrheumdis-2021-221847.

Read the full article here: link
Objective: In the anifrolumab systemic lupus erythematosus (SLE) trial programme, there was one trial (TULIP-1) in which BILAG-based Composite Lupus Assessment (BICLA) responses favoured anifrolumab over placebo, but the SLE Responder Index (SRI(4)) treatment difference was not significant. We investigated the degree of concordance between BICLA and SRI(4) across anifrolumab trials in order to better understand drivers of discrepant SLE trial results.

Conclusions: Across trials, most patients had concordant BICLA/SRI(4) outcomes and dual BICLA/SRI(4) responses favoured anifrolumab. A BICLA non-responder/SRI(4) responder subgroup was identified where imbalances of key factors driving the BICLA/SRI(4) discordance (disease activity, glucocorticoid taper) disproportionately favoured the TULIP-1 placebo group. Careful attention to baseline disease activity and monitoring glucocorticoid taper variation will be essential in future SLE trials.

This video summarises a scientific article published by BMJ Publishing Group Limited (BMJ). The content of this video has not been peer-reviewed and does not constitute medical advice. Any opinions expressed are solely those of the contributors. Viewers should be aware that professionals in the field may have different opinions. BMJ does not endorse any opinions expressed or recommendations discussed. Viewers should not use the content of the video as the basis for any medical treatment. BMJ disclaims all liability and responsibility arising from any reliance placed on the content.

Podcasts